Grant winners

May 23, 2013

Action Medical Research

Research Project Grants

Bacterial meningitis in newborn babies: harnessing the body’s natural defences

Leverhulme Trust

Research Leadership Awards
Sciences

  • Award winner: Feliciano Giustino
  • Institution: University of Oxford
  • Value: £899,876

Multiphysics modelling of solar energy harvesting in biomimetic photovoltaics

  • Award winner: Martin Hairer
  • Institution: University of Warwick
  • Value: £943,664

Singular stochastic partial differential equations

  • Award winner: Stuart Humphries
  • Institution: University of Hull
  • Value: £941,132

Form and function in a microbial world

  • Award winner: Jurriaan Ton
  • Institution: University of Sheffield
  • Value: £902,625

Priming plant defence: from its onset to transgenerational maintenance

Major Research Fellowships

  • Award winner: James Raven
  • Institution: University of Essex
  • Value: £146,799

Chance and containment: state lotteries in Britain and Europe c.1600- 1850

  • Award winner: Jennifer Richards
  • Institution: Newcastle University
  • Value: £90,957

Useful books: reading and talking in the English Renaissance

  • Award winner: Robert Swanson
  • Institution: University of Birmingham
  • Value: £157,128

The English parish, c.1290-c.1535

  • Award winner: Peter Wade
  • Institution: University of Manchester
  • Value: £94,838

Race, nation and genomics: biology and society

Royal Society

Wolfson Research Merit Awards
Awards are worth £10,000-£30,000 a year, which is a salary enhancement

  • Award winner: Gert Aarts
  • Institution: Swansea University

An exploration of the strong interaction under extreme conditions

Nanoscale multiferroic materials and heterostructures for oxide electronics

In detail

National Institute for Health Research

Award winner: Tim Maughan
Institution: University of Oxford
Value: £3,525,623

Molecular selection of therapy in metastatic colorectal cancer: a molecularly stratified randomised controlled trial programme (FOCUS 4)

Tests that can be done on tumour samples from patients with advanced bowel cancer may help to select the best treatment options for an individual patient. There are a number of new cancer drugs that are more likely to be helpful in one subtype of bowel cancer than in another. The FOCUS 4 trial aims to recruit more than 1,500 patients across the UK to evaluate how well these new drugs work. Patients diagnosed with bowel cancer that is inoperable or has spread into other areas of the body will be invited to join this trial. Those who join will start on a course of chemotherapy for up to 16 weeks. In this time, a piece of the patient’s tumour will be analysed using two sorts of tests to find out more about its molecular make-up. The results will place the individual into subtypes of colorectal cancer. Patients will be assessed during and after the 16 weeks of chemotherapy to see how the tumour is responding to standard treatment.

You've reached your article limit.

Register to continue

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments
Register

Have your say

Log in or register to post comments

Featured Jobs

Most Commented

Monster behind man at desk

Despite all that’s been done to improve doctoral study, horror stories keep coming. Here three students relate PhD nightmares while two academics advise on how to ensure a successful supervision

celebrate, cheer, tef results

Emilie Murphy calls on those who challenged the teaching excellence framework methodology in the past to stop sharing their university ratings with pride

Sir Christopher Snowden, former Universities UK president, attacks ratings in wake of Southampton’s bronze award

Reflection of man in cracked mirror

To defend the values of reason from political attack we need to be more discriminating about the claims made in its name, says John Hendry

But the highest value UK spin-off companies mainly come from research-intensive universities, latest figures show